News
Empowering the biopharma industry with field-leading foundation models.
Recent News
Presentations & Publications
|
October 21, 2025
Triangle Multiplication Is All You Need For Biomolecular Structure Representations
arXIV
Press
|
February 20, 2025
Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration
Incyte
Press
|
December 11, 2024
Genesis Therapeutics Expands Leadership Team with Appointments of Chief Scientific Officer, SVP of Engineering, and Board Chairman
Business Wire
Presentations & Publications
|
November 20, 2024
Boltz-1: Democratizing Biomolecular Interaction Modeling
bioRxiv
Press
|
November 13, 2024
Genesis Therapeutics Announces New Equity Investment and Collaboration with NVIDIA to Optimize Key Computational Methods for AI-powered Drug Discovery
Business Wire
Press
|
September 10, 2024
Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies
Business Wire
Press
|
September 10, 2024
Gilead partners with AI startup Genesis Therapeutics to make small molecule drugs
Endpoints News
Presentations & Publications
|
July 22, 2024
ICML Talk: Driving Small Molecule Drug Discovery with Generative Modeling
Genesis
Join Us
Opportunities in AI and Physics Research
Our molecular AI research team is pioneering new frameworks for drug discovery, at the intersection of multi-dimensional ML models and physical simulation. See opportunities in software engineering, machine learning and computation chemistry.
Software Engineering
Machine Learning
Computational Chemistry
